CLAIMS

Claims 1-4, 7-8, 10-15, 32-34 and 38 are currently pending in this application. Please amend Claims 1-4; 7-15; and 32 without prejudice or disclaimer of the subject matter thereof. are Currently Amended. Claims 5, 6 and 9 have been withdrawn without prejudice or disclaimer of the subject matter thereof. Claims 16-31, 35-37 and 39 were previously cancelled without prejudice or disclaimer of the subject matter thereof.

- 1. (Currently Amended) A method for determining the presence of a lipid product of a lipid phosphatase, comprising: (a) providing a solution containing a substrate lipid of a lipid phosphatase; (b) contacting the substrate lipid of the lipid phosphatase with a lipid detector protein containing a lipid recognition motif having a binding specificity for a product lipid of the lipid phosphatase; and determining a change in concentration of at least one of the following: substrate lipid, lipid dectector protein, and lipid product, wherein a change in concentration for any of the above substances between steps (a) and (b) indicates that said product lipid is present in said solution.
- 2. (Currently Amended) The method according to claim 1, wherein the method is a direct assay or a competitive assay wherein said product lipid has a stronger affinity to said lipid detector protein than said substrate lipid.
- 3. (Currently Amended) The method according to claim 1, wherein said lipid detector protein is an antibody against said product lipid or a lipid recognition protein (LRP) with specificity for said product lipid.
- 4. (Currently Amended) The method according to claim 3, wherein said lipid recognition protein contains an affinity tag fusion with PH or other lipid-binding domains.
- 5. (Withdrawn) The lipid phosphatase assay method according to claim 1, wherein said assay is a plate-based assay.

Application No. 10/712,073 Attorney Docket No: 007262-30 US

- 6. (Withdrawn) The lipid phosphatase assay method according to claim 5, wherein
- said assay is an enzyme linked immunosorbent assay (ELISA).
- 7. (Currently Amended) The method according to claim 1, further comprising: prior to
- contacting said lipid detector protein to the solution, coating a substrate of an assay plate with
- a non-radioactively labeled substrate lipid.
- 8. (Currently Amended) The method according to claim 7, wherein said assay plate is
- coated with streptavidin, glutathione or Protein A.
- 9. (Withdrawn) The lipid phosphatase assay method according to claim 1, wherein
- said assay is an amplified luminescence proximity homogenous assay (ALPHA).
- 10. (Currently Amended) The method according to claim 1, wherein said method is a
- fluorogenic assay.
- 11. (Currently Amended) The method according to claim 10, wherein the assay is a
- fluorescence polarization (FP) assay, fluorescence resonance energy transfer (FRET) assay or
- time-resolved fluorescence resonance energy transfer (TR-FRET) assay.
- 12. (Currently Amended) The method according to claim 1, wherein additional lipids
- are present in said solution.
- 13. (Currently Amended) The method according to claim 1, wherein said lipid
- phosphatase acts on any PIPn and is a member selected from the group consisting of SHIP1.
- SHIP2, PTEN, PTPRQ, SKIP, Myotubularin, MTMR2 and OCRL1.
- 14. (Currently Amended) The method according to claim 1, wherein said substrate
- lipid is PI(3,4,5)P₃, PI(3,4)P₂, PI(3,5)P₂, PI(4,5)P₂, PI(3)P, PI(4)P, or PI(5)P.

15. (Currently Amended) The method according to claim 1, wherein said product lipid is PI(3,4)P₂, PI(4,5)P₂, PI(3,5)P₂, PI(3)P, PI(4)P, PI(5)P, or Phosphatidyl Inositol.

16 - 31. (Cancelled)

32. (Currently Amended) A method for screening a disease caused alteration of a lipid phosphatase comprising the step of using the lipid phosphatase method of claim 1 to detect changes in the lipid phosphatase activity in bodily tissue, blood, or serum samples whereby detection of a change indicates a disease caused alteration of a lipid phosphatase.

33. (Original) The method of claim 32, wherein the disease is non-insulin dependant, Type II diabetes.

34. (Original) The method of claim 32, wherein the disease is Cowden's disease or cancer.

35 - 37. (Cancelled)

38. (Original) A method for screening a compound having an enhancing or inhibiting effect on a lipid phosphatase comprising the step of using the lipid phosphatase assay method of claim 1 to detect changes in the lipid phosphatase activity.

39. (Cancelled)